To help accelerate research into new treatments for acute myeloid leukemia and myelodysplastic syndrome, Thermo Fisher Scientific Inc. is partnering with NCI on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
Thermo Fisher, NCI collaborate to advance myeloid cancer research, treatment utilizing next-gen sequencing technology
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins.
Cancer centers that continue to experience pandemic-induced shortages in staffing their clinical research enterprise may soon be able to rely on support from NCI’s Virtual Clinical Trials Office to open studies and accrue patients.
Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.
The NCI Board of Scientific Advisors approved five new concepts and 17 reissue concepts at a joint meeting of the BSA and the National Cancer Advisory Board June 11-12.
Edward Sondik, former director of the National Center for Health Statistics at CDC, who previously served as an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control, died on June 25. He was 82.
